Do analysts recommend GRML or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Greenland Mines Ltd. Common Stock 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Is GRML or JUNS more profitable?

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets Greenland Mines Ltd. Common Stock N/A -109.40% -98.80% Jupiter Neurosciences N/A -1,314.62% -228.63%

Do analysts rate MRKR or JUNS?

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 681.25%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Marker Therapeutics 1 Sell rating(s) 1 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.25 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer VYNE or JUNS?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score VYNE Therapeutics 1 Sell rating(s) 3 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.75 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts prefer JUNS or TXMD?

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00 TherapeuticsMD 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Do analysts rate NCEL or JUNS?

NLS Pharmaceutics presently has a consensus target price of $23.00, suggesting a potential upside of 479.35%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Jupiter Neurosciences. Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score NLS Pharmaceutics 1 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 2.00 Jupiter Neurosciences 1 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 1.00

Which has stronger earnings & valuation, NCEL or JUNS?

NLS Pharmaceutics has higher earnings, but lower revenue than Jupiter Neurosciences. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio NLS Pharmaceutics N/A N/A -$8.30M N/A N/A Jupiter Neurosciences $20K 299.31 -$8.65M -$0.27 N/A

Is NCEL or JUNS more profitable?

NLS Pharmaceutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity. Company Net Margins Return on Equity Return on Assets NLS Pharmaceutics N/A N/A N/A Jupiter Neurosciences N/A -1,314.62% -228.63%

Jupiter Neurosciences (JUNS) Competitors

$0.16 -0.01 (-4.35%)

Closing price 04:00 PM Eastern

Extended Trading

$0.16 0.00 (0.00%)

As of 07:15 PM Eastern

Compare

JUNS vs. GRML, MRKR, VYNE, TXMD, and NCEL

Should you buy Jupiter Neurosciences stock or one of its competitors? MarketBeat compares Jupiter Neurosciences with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Jupiter Neurosciences include Greenland Mines Ltd. Common Stock (GRML), Marker Therapeutics (MRKR), VYNE Therapeutics (VYNE), TherapeuticsMD (TXMD), and NLS Pharmaceutics (NCEL). These companies are all part of the "med - drugs" industry.

How does Jupiter Neurosciences compare to Greenland Mines Ltd. Common Stock?

Greenland Mines Ltd. Common Stock (NASDAQ:GRML) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better stock? We will contrast the two businesses based on the strength of their media sentiment, analyst recommendations, institutional ownership, profitability, valuation, risk, dividends and earnings.

Greenland Mines Ltd. Common Stock has a beta of 7.05, meaning that its share price is 605% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.73, meaning that its share price is 73% more volatile than the broader market.

Greenland Mines Ltd. Common Stock's return on equity of -109.40% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Greenland Mines Ltd. Common Stock	N/A	-109.40%	-98.80%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Greenland Mines Ltd. Common Stock	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

20.1% of Greenland Mines Ltd. Common Stock shares are owned by institutional investors. 11.3% of Greenland Mines Ltd. Common Stock shares are owned by insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

In the previous week, Greenland Mines Ltd. Common Stock had 1 more articles in the media than Jupiter Neurosciences. MarketBeat recorded 2 mentions for Greenland Mines Ltd. Common Stock and 1 mentions for Jupiter Neurosciences. Greenland Mines Ltd. Common Stock's average media sentiment score of 0.21 beat Jupiter Neurosciences' score of 0.00 indicating that Greenland Mines Ltd. Common Stock is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Greenland Mines Ltd. Common Stock	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Jupiter Neurosciences	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Jupiter Neurosciences has higher revenue and earnings than Greenland Mines Ltd. Common Stock. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than Greenland Mines Ltd. Common Stock, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Greenland Mines Ltd. Common Stock	N/A	N/A	-$10.55M	-$0.32	N/A
Jupiter Neurosciences	$20K	299.31	-$8.65M	-$0.27	N/A

Summary

Greenland Mines Ltd. Common Stock beats Jupiter Neurosciences on 7 of the 11 factors compared between the two stocks.

How does Jupiter Neurosciences compare to Marker Therapeutics?

Marker Therapeutics (NASDAQ:MRKR) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior investment? We will compare the two companies based on the strength of their profitability, media sentiment, risk, analyst recommendations, earnings, institutional ownership, valuation and dividends.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than Marker Therapeutics. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for Marker Therapeutics. Marker Therapeutics' average media sentiment score of 0.00 equaled Jupiter Neurosciences'average media sentiment score.

Company	Overall Sentiment
Marker Therapeutics	Neutral
Jupiter Neurosciences	Neutral

Jupiter Neurosciences has lower revenue, but higher earnings than Marker Therapeutics. Marker Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Marker Therapeutics	$3.55M	6.01	-$12.16M	-$0.61	N/A
Jupiter Neurosciences	$20K	299.31	-$8.65M	-$0.27	N/A

22.4% of Marker Therapeutics shares are held by institutional investors. 5.7% of Marker Therapeutics shares are held by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Jupiter Neurosciences has a net margin of 0.00% compared to Marker Therapeutics' net margin of -343.03%. Marker Therapeutics' return on equity of -73.29% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Marker Therapeutics	-343.03%	-73.29%	-59.70%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Marker Therapeutics has a beta of 1.45, indicating that its stock price is 45% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.73, indicating that its stock price is 73% more volatile than the broader market.

Marker Therapeutics currently has a consensus target price of $10.00, suggesting a potential upside of 681.25%. Given Marker Therapeutics' stronger consensus rating and higher possible upside, analysts clearly believe Marker Therapeutics is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Marker Therapeutics	1 Sell rating(s)	1 Hold rating(s)	2 Buy rating(s)	0 Strong Buy rating(s)	2.25
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jupiter Neurosciences beats Marker Therapeutics on 8 of the 15 factors compared between the two stocks.

How does Jupiter Neurosciences compare to VYNE Therapeutics?

VYNE Therapeutics (NASDAQ:VYNE) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their analyst recommendations, institutional ownership, profitability, valuation, risk, dividends, media sentiment and earnings.

Jupiter Neurosciences has a net margin of 0.00% compared to VYNE Therapeutics' net margin of -4,726.21%. VYNE Therapeutics' return on equity of -70.42% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
VYNE Therapeutics	-4,726.21%	-70.42%	-63.46%
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

Jupiter Neurosciences has lower revenue, but higher earnings than VYNE Therapeutics. VYNE Therapeutics is trading at a lower price-to-earnings ratio than Jupiter Neurosciences, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
VYNE Therapeutics	$570K	47.26	-$26.48M	-$0.38	N/A
Jupiter Neurosciences	$20K	299.31	-$8.65M	-$0.27	N/A

83.8% of VYNE Therapeutics shares are held by institutional investors. 3.0% of VYNE Therapeutics shares are held by company insiders. Comparatively, 38.6% of Jupiter Neurosciences shares are held by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

VYNE Therapeutics has a beta of 2, meaning that its stock price is 100% more volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.73, meaning that its stock price is 73% more volatile than the broader market.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than VYNE Therapeutics. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for VYNE Therapeutics. VYNE Therapeutics' average media sentiment score of 0.00 equaled Jupiter Neurosciences'average media sentiment score.

Company	Overall Sentiment
VYNE Therapeutics	Neutral
Jupiter Neurosciences	Neutral

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
VYNE Therapeutics	1 Sell rating(s)	3 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.75
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Jupiter Neurosciences beats VYNE Therapeutics on 7 of the 13 factors compared between the two stocks.

How does Jupiter Neurosciences compare to TherapeuticsMD?

Jupiter Neurosciences (NASDAQ:JUNS) and TherapeuticsMD (NASDAQ:TXMD) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their media sentiment, valuation, analyst recommendations, profitability, dividends, institutional ownership, risk and earnings.

30.7% of TherapeuticsMD shares are owned by institutional investors. 38.6% of Jupiter Neurosciences shares are owned by company insiders. Comparatively, 1.7% of TherapeuticsMD shares are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.

TherapeuticsMD has a net margin of 5.34% compared to Jupiter Neurosciences' net margin of 0.00%. TherapeuticsMD's return on equity of 0.32% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%
TherapeuticsMD	5.34%	0.32%	0.23%

TherapeuticsMD has higher revenue and earnings than Jupiter Neurosciences. Jupiter Neurosciences is trading at a lower price-to-earnings ratio than TherapeuticsMD, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Jupiter Neurosciences	$20K	299.31	-$8.65M	-$0.27	N/A
TherapeuticsMD	$3.02M	8.08	-$570K	$0.06	35.17

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
TherapeuticsMD	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Jupiter Neurosciences has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market. Comparatively, TherapeuticsMD has a beta of 0.59, suggesting that its stock price is 41% less volatile than the broader market.

In the previous week, Jupiter Neurosciences had 1 more articles in the media than TherapeuticsMD. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for TherapeuticsMD. Jupiter Neurosciences' average media sentiment score of 0.00 equaled TherapeuticsMD'saverage media sentiment score.

Company	Overall Sentiment
Jupiter Neurosciences	Neutral
TherapeuticsMD	Neutral

Summary

TherapeuticsMD beats Jupiter Neurosciences on 8 of the 12 factors compared between the two stocks.

How does Jupiter Neurosciences compare to NLS Pharmaceutics?

NLS Pharmaceutics (NASDAQ:NCEL) and Jupiter Neurosciences (NASDAQ:JUNS) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their media sentiment, risk, institutional ownership, valuation, profitability, earnings, analyst recommendations and dividends.

NLS Pharmaceutics' return on equity of 0.00% beat Jupiter Neurosciences' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
NLS Pharmaceutics	N/A	N/A	N/A
Jupiter Neurosciences	N/A	-1,314.62%	-228.63%

NLS Pharmaceutics has a beta of 0.93, suggesting that its stock price is 7% less volatile than the broader market. Comparatively, Jupiter Neurosciences has a beta of 1.73, suggesting that its stock price is 73% more volatile than the broader market.

NLS Pharmaceutics has higher earnings, but lower revenue than Jupiter Neurosciences.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
NLS Pharmaceutics	N/A	N/A	-$8.30M	N/A	N/A
Jupiter Neurosciences	$20K	299.31	-$8.65M	-$0.27	N/A

In the previous week, Jupiter Neurosciences had 1 more articles in the media than NLS Pharmaceutics. MarketBeat recorded 1 mentions for Jupiter Neurosciences and 0 mentions for NLS Pharmaceutics. NLS Pharmaceutics' average media sentiment score of 1.00 beat Jupiter Neurosciences' score of 0.00 indicating that NLS Pharmaceutics is being referred to more favorably in the media.

Company	Overall Sentiment
NLS Pharmaceutics	Positive
Jupiter Neurosciences	Neutral

NLS Pharmaceutics presently has a consensus target price of $23.00, suggesting a potential upside of 479.35%. Given NLS Pharmaceutics' stronger consensus rating and higher possible upside, equities research analysts plainly believe NLS Pharmaceutics is more favorable than Jupiter Neurosciences.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
NLS Pharmaceutics	1 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	2.00
Jupiter Neurosciences	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

NLS Pharmaceutics beats Jupiter Neurosciences on 7 of the 10 factors compared between the two stocks.

Get Jupiter Neurosciences News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding JUNS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

JUNS vs. The Competition

Export

Metric	Jupiter Neurosciences	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$6.26M	$3.07B	$6.90B	$12.28B
Dividend Yield	N/A	2.05%	2.67%	9.39%
P/E Ratio	-0.61	20.20	27.10	23.94
Price / Sales	299.31	340.68	517.51	91.92
Price / Cash	N/A	27.11	26.68	47.25
Price / Book	-3.30	4.20	10.66	6.14
Net Income	-$8.65M	$65.94M	$3.60B	$331.74M
7 Day Performance	-9.19%	-3.04%	-1.51%	-1.72%
1 Month Performance	-30.67%	-1.30%	1.11%	-1.44%
1 Year Performance	-89.81%	16.06%	23.77%	16.97%

Jupiter Neurosciences Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
JUNS Jupiter Neurosciences	0.2521 of 5 stars	$0.17 -4.3%	N/A	-89.4%	$6.26M	$20K	N/A	5	News Coverage
GRML Greenland Mines Ltd. Common Stock	0.2315 of 5 stars	$0.18 +0.9%	N/A	-83.8%	$24.88M	N/A	N/A	5
MRKR Marker Therapeutics	2.355 of 5 stars	$1.41 -2.1%	$10.00 +609.2%	-22.9%	$24.01M	$3.55M	N/A	60
VYNE VYNE Therapeutics	1.0657 of 5 stars	$0.76 +6.5%	N/A	-34.4%	$23.71M	$570K	N/A	30
TXMD TherapeuticsMD	0.4184 of 5 stars	$1.94 -1.5%	N/A	+79.1%	$22.80M	$3.02M	32.33	420	Positive News Gap Down

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:JUNS) was last updated on 7/20/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. GRML, MRKR, VYNE, TXMD, and NCEL

How does Jupiter Neurosciences compare to Greenland Mines Ltd. Common Stock?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Summary

How does Jupiter Neurosciences compare to NLS Pharmaceutics?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Jupiter Neurosciences (JUNS) Competitors

JUNS vs. GRML, MRKR, VYNE, TXMD, and NCEL

How does Jupiter Neurosciences compare to Greenland Mines Ltd. Common Stock?

Which has more risk & volatility, GRML or JUNS?

Is GRML or JUNS more profitable?

Do analysts recommend GRML or JUNS?

Do insiders and institutionals believe in GRML or JUNS?

Does the media favor GRML or JUNS?

Which has better valuation & earnings, GRML or JUNS?

Summary

How does Jupiter Neurosciences compare to Marker Therapeutics?

Does the media favor MRKR or JUNS?

Which has better valuation and earnings, MRKR or JUNS?

Do institutionals & insiders hold more shares of MRKR or JUNS?

Is MRKR or JUNS more profitable?

Which has more risk & volatility, MRKR or JUNS?

Do analysts rate MRKR or JUNS?

Summary

How does Jupiter Neurosciences compare to VYNE Therapeutics?

Is VYNE or JUNS more profitable?

Which has stronger valuation & earnings, VYNE or JUNS?

Do insiders and institutionals have more ownership in VYNE or JUNS?

Which has more risk & volatility, VYNE or JUNS?

Does the media refer more to VYNE or JUNS?

Do analysts prefer VYNE or JUNS?

Summary

How does Jupiter Neurosciences compare to TherapeuticsMD?

Do institutionals & insiders hold more shares of JUNS or TXMD?

Is JUNS or TXMD more profitable?

Which has preferable valuation and earnings, JUNS or TXMD?

Do analysts prefer JUNS or TXMD?

Which has more volatility & risk, JUNS or TXMD?

Does the media favor JUNS or TXMD?

Summary

How does Jupiter Neurosciences compare to NLS Pharmaceutics?

Is NCEL or JUNS more profitable?

Which has more volatility & risk, NCEL or JUNS?

Which has stronger earnings & valuation, NCEL or JUNS?

Does the media prefer NCEL or JUNS?

Do analysts rate NCEL or JUNS?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

JUNS vs. The Competition

Jupiter Neurosciences Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools